InvestorsHub Logo
Followers 15
Posts 1647
Boards Moderated 0
Alias Born 05/15/2015

Re: None

Sunday, 10/23/2016 10:52:39 PM

Sunday, October 23, 2016 10:52:39 PM

Post# of 19457
GOVX: HVTN-114. HIV human vax trial. 12/2016.


The target date was June 2016.

Now, the important news released at the end of last week affirms the start date as December, 2016.

Truly incredible that a company this far along in creating an HIV vaccine has a total market cap of $3.5 million dollars.

GOVX a true catalyst play now on multiple fronts.

http://www.stockhouse.com/news/press-releases/2016/10/20/geovax-hiv-vaccine-clinical-data-presented-at-hivr4p-conference
Dr. Robinson continued, "We now look forward to the commencement of the HVTN 114 trial, which will begin the evaluation of our vaccine in combination with a protein boost. HVTN 114 is scheduled to start in December of this year."


Link:

http://www.avac.org/trial/hvtn-114
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GOVX News